Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients

American Journal of Pathology

Volumn 183, Issue 5, 2013, Pages 1446-1460

  Onsum, Matthew D ^a   Geretti, Elena ^a   Paragas, Violette ^a   Kudla, Arthur J ^a   Moulis, Sharon P ^a   Luus, Lia ^a   Wickham, Thomas J ^a   McDonagh, Charlotte F ^a   Macbeath, Gavin ^a   Hendriks, Bart S ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; ASSAY; CELL HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC HETEROGENEITY; HUMANS; MICE; MICE, NUDE; NEOPLASMS; RECEPTOR, ERBB-2; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SINGLE-CELL ANALYSIS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84884514632     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.07.015     Document Type: Article

References (49)

1. F. Petrelli, and S. Barni Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis Med Oncol 29 2012 2586 2593
2. S. Scholl, P. Beuzeboc, and P. Pouillart Targeting HER2 in other tumor types Ann Oncol 12 Suppl 1 2001 S81 S87
3. G. Sauter, J. Lee, J.M. Bartlett, D.J. Slamon, and M.F. Press Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 2009 1323 1333
4. K. Bullock, and K. Blackwell Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer Oncologist 13 2008 515 525
5. S. Paik, C. Kim, and N. Wolmark HER2 status and benefit from adjuvant trastuzumab in breast cancer N Engl J Med 358 2008 1409 1411
6. S. Simonetti, R. Russo, G. Ciancia, V. Altieri, G. De Rosa, and L. Insabato Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17 Int J Surg Pathol 17 2009 198 205
7. V. Caner, N.S. Turk, F. Duzcan, N.L. Tufan, E.C. Kelten, S. Zencir, Y. Dodurga, H. Bagci, and S.E. Duzcan No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas Pathol Oncol Res 14 2008 261 266
8. R. Simon, R. Atefy, U. Wagner, T. Forster, A. Fijan, J. Bruderer, K. Wilber, M.J. Mihatsch, T. Gasser, and G. Sauter HER-2 and TOP2A gene amplification in urinary bladder carcinoma [in German] Verh Dtsch Ges Pathol 86 2002 176 183
9. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, L.M. Adler, J.S. Berek, J.A. Chapman, P.A. DiSilvestro, I.R. Horowitz, and J.V. Fiorica Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 2010 15 20
10. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, L.E. De Las Casas, S. Korourian, E. Tian, J.J. Roman, A. Burnett, and S. Pecorelli Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization Gynecol Oncol 98 2005 24 30
11. G.E. Konecny, L. Santos, B. Winterhoff, M. Hatmal, G.L. Keeney, A. Mariani, M. Jones, C. Neuper, B. Thomas, L. Muderspach, D. Riehle, H.J. Wang, S. Dowdy, K.C. Podratz, and M.F. Press HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer Br J Cancer 100 2009 89 95
12. S. Kuyama, K. Hotta, M. Tabata, Y. Segawa, Y. Fujiwara, N. Takigawa, K. Kiura, H. Ueoka, K. Eguchi, and M. Tanimoto Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer J Thorac Oncol 3 2008 477 482
13. C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry Clin Cancer Res 9 2003 3645 3652
14. K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, D. Ercan, A. Rogers, M. Roncalli, M. Takeda, Y. Fujisaka, J. Philips, T. Shimizu, O. Maenishi, Y. Cho, J. Sun, A. Destro, K. Taira, K. Takeda, T. Okabe, J. Swanson, H. Itoh, M. Takada, E. Lifshits, K. Okuno, J.A. Engelman, R.A. Shivdasani, K. Nishio, M. Fukuoka, M. Varella-Garcia, K. Nakagawa, and P.A. Janne Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Sci Transl Med 3 2011 99ra86
15. R.J. Lammers, and J.A. Witjes Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues Expert Rev Anticancer Ther 11 2011 853 858
16. Y. Bai, J. Tolles, H. Cheng, S. Siddiqui, A. Gopinath, E. Pectasides, R.L. Camp, D.L. Rimm, and A.M. Molinaro Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables Lab Invest 91 2011 1253 1261
17. F.R. Fritzsche, G. Kristiansen, A. Boesl, M. Burkhardt, S. Pahl, A. Dankof, M. Dietel, and E. Dahl Tissue pretreatment with formic acid might lower HercepTest scores in breast cancer Diagn Mol Pathol 15 2006 237 242
18. T.W. Jacobs, A.M. Gown, H. Yaziji, M.J. Barnes, and S.J. Schnitt Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol 17 1999 1974 1982
19. S. Siddiqui, and D.L. Rimm Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry Breast Cancer Res 12 2010 113
20. B.P. Portier, Z. Wang, E. Downs-Kelly, J.J. Rowe, D. Patil, C. Lanigan, G.T. Budd, D.G. Hicks, D.L. Rimm, and R.R. Tubbs Delay to formalin fixation "cold ischemia time": effect on ERBB2 detection by in-situ hybridization and immunohistochemistry Mod Pathol 26 2013 1 9
21. M.F. Press, G. Sauter, L. Bernstein, I.E. Villalobos, M. Mirlacher, J.Y. Zhou, R. Wardeh, Y.T. Li, R. Guzman, Y. Ma, J. Sullivan-Halley, A. Santiago, J.M. Park, A. Riva, and D.J. Slamon Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials Clin Cancer Res 11 2005 6598 6607
22. S.J. Schnitt, and T.W. Jacobs Current status of HER2 testing: caught between a rock and a hard place Am J Clin Pathol 116 2001 806 810
23. J. Rüschoff, W. Hanna, M. Bilous, M. Hofmann, R.Y. Osamura, F. Penault-Llorca, M. van de Vijver, and G. Viale HER2 testing in gastric cancer: a practical approach Mod Pathol 25 2012 637 650
24. H. Choritz, G. Busche, and H. Kreipe Quality assessment of HER2 testing by monitoring of positivity rates Virchows Arch 459 2011 283 289
25. D.G. Hicks, and R.R. Tubbs Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines Hum Pathol 36 2005 250 261
26. I.T. Yeh, M.A. Martin, R.S. Robetorye, A.R. Bolla, C. McCaskill, R.K. Shah, M.E. Gorre, M.S. Mohammed, and S.R. Gunn Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event Mod Pathol 22 2009 1169 1175
27. C.H. Tse, H.C. Hwang, L.C. Goldstein, P.L. Kandalaft, J.C. Wiley, S.J. Kussick, and A.M. Gown Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy J Clin Oncol 29 2011 4168 4174
28. A.C. Wolff, M.E. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, W.M. Hanna, A. Langer, L.M. McShane, S. Paik, M.D. Pegram, E.A. Perez, M.F. Press, A. Rhodes, C. Sturgeon, S.E. Taube, R. Tubbs, G.H. Vance, M. van de Vijver, T.M. Wheeler, and D.F. Hayes American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
29. A. Stenzinger, M. von Winterfeld, S. Aulmann, A. Warth, W. Weichert, C. Denkert, J. Ruschoff, M. Dietel, and F. Klauschen Quantitative analysis of diagnostic guidelines for HER2-status assessment J Mol Diagn 14 2012 199 205
30. N.A. Moatamed, G. Nanjangud, R. Pucci, A. Lowe, I.P. Shintaku, S. Shapourifar-Tehrani, N. Rao, D.Y. Lu, and S.K. Apple Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer Am J Clin Pathol 136 2011 754 761
31. T. Khoury, S. Sait, H. Hwang, R. Chandrasekhar, G. Wilding, D. Tan, and S. Kulkarni Delay to formalin fixation effect on breast biomarkers Mod Pathol 22 2009 1457 1467
32. D.M. Minot, B.R. Kipp, R.M. Root, R.G. Meyer, C.A. Reynolds, A. Nassar, M.R. Henry, and A.C. Clayton Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH Am J Clin Pathol 132 2009 133 138
33. G. Turashvili, S. Leung, D. Turbin, K. Montgomery, B. Gilks, R. West, M. Carrier, D. Huntsman, and S. Aparicio Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis BMC Cancer 9 2009 165
34. J. Yang, H. Luo, Y. Li, J. Li, Z. Cai, X. Su, D. Dai, W. Du, T. Chen, and M. Chen Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens Cell Biochem Biophys 62 2012 221 228
35. S. Lee, W.B. de Boer, S. Fermoyle, M. Platten, and M.P. Kumarasinghe Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections Histopathology 59 2011 832 840
36. A. McCabe, M. Dolled-Filhart, R.L. Camp, and D.L. Rimm Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis J Natl Cancer Inst 97 2005 1808 1815
37. D. Faratian, J. Christiansen, M. Gustavson, C. Jones, C. Scott, I. Um, and D.J. Harrison Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence J Vis Exp 56 2011 e3334
38. E.H. Simpson Measurement of diversity Nature 163 1949 688
39. B. Schoeberl, E.A. Pace, J.B. Fitzgerald, B.D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, V. Grantcharova, N. Kohli, K.A. West, M. Leszczyniecka, M.J. Feldhaus, A.J. Kudla, and U.B. Nielsen Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis Sci Signal 2 2009 ra31
40. A.M. Feldman, B.H. Lorell, and S.E. Reis Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity Circulation 102 2000 272 274
41. L. Gianni, E. Salvatorelli, and G. Minotti Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes Cardiovasc Toxicol 7 2007 67 71
42. J.G. Reynolds, E. Geretti, B.S. Hendriks, H. Lee, S.C. Leonard, S.G. Klinz, C.O. Noble, P.B. Lücker, P.W. Zandstra, D.C. Drummond, K.J. Olivier Jr., U.B. Nielsen, C. Niyikiza, S.V. Agresta, and T.J. Wickham HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity Toxicol Appl Pharmacol 262 2012 1 10
43. J.M. Giltnane, A. Molinaro, H. Cheng, A. Robinson, D. Turbin, K. Gelmon, D. Huntsman, and D.L. Rimm Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer Arch Pathol Lab Med 132 2008 1635 1647
44. A. Dimou, S. Agarwal, V. Anagnostou, H. Viray, S. Christensen, B. Gould Rothberg, V. Zolota, K. Syrigos, and D.L. Rimm Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer Am J Pathol 179 2011 580 589
45. S. Wang, M.H. Saboorian, E.P. Frenkel, B.B. Haley, M.T. Siddiqui, S. Gokaslan, F.H. Wians Jr., L. Hynan, and R. Ashfaq Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard Am J Clin Pathol 116 2001 495 503
46. M.W. Kilpatrick, C.E. Sheehan, W.A. Marganski, T. Tafas, M.S. Ross, and J.S. Ross Determination of HER2 gene status by fully automated fluorescence microscopy Anal Quant Cytol Histol 33 2011 205 210
47. J. Tolles, Y. Bai, M. Baquero, L.N. Harris, D.L. Rimm, and A.M. Molinaro Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma Breast Cancer Res 13 2011 R51
48. H.H. Yoon, Q. Shi, W.R. Sukov, M.A. Lewis, C.A. Sattler, A.E. Wiktor, T.T. Wu, R.B. Diasio, R.B. Jenkins, and F.A. Sinicrope Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma J Clin Oncol 30 2012 3932 3938
49. C.F. McDonagh, A. Huhalov, B.D. Harms, S. Adams, V. Paragas, S. Oyama, B. Zhang, L. Luus, R. Overland, S. Nguyen, J. Gu, N. Kohli, M. Wallace, M.J. Feldhaus, A.J. Kudla, B. Schoeberl, and U.B. Nielsen Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 Mol Cancer Ther 11 2012 582 593